We show here that nerve growth factor (NGF), the canonical neurotrophic factor, is synthesized and released by breast cancer cells. High levels of NGF transcript and protein were detected in breast cancer cells by reverse transcription-PCR, Western blotting, ELISA assay and immunohistochemistry. Conversely, NGF production could not be detected in normal breast epithelial cells at either the transcriptional or protein level. Confocal analysis indicated the presence of NGF within classical secretion vesicles. Breast cancer cell-produced NGF was biologically active, as demonstrated by its ability to induce the neuronal differentiation of embryonic neural precursor cells. Importantly, the constitutive growth of breast cancer cells was strongly inhibited by either NGF-neutralizing antibodies or K-252a, a pharmacological inhibitor of NGF receptor TrkA, indicating the existence of an NGF autocrine loop. Together, our data demonstrate the physiological relevance of NGF in breast cancer and its potential interest as a marker and therapeutic target.
Introduction
Breast cancer is a leading cause of death among women and thus a major problem for public health. Improved treatments derived from a better understanding of the molecular basis of breast cancer cell growth are now emerging (Bange et al., 2001) . This is best illustrated by the development of new therapeutic strategies based on the inhibition of the tyrosine kinase receptor Erb-B2, a member of the epidermal growth factor (EGF) receptor family. Erb-B2 overexpression in breast cancer cells has been demonstrated, and its specific inhibition with Herceptin, a truncated blocking antibody, has been successfully clinically trialed, to date with promising results (Colomer et al., 2001) . However, the growth of breast cancer cells can be regulated by other growth factors that either stimulate or inhibit their proliferation, migration and differentiation, thus acting in concert to promote tumor growth and metastasis (Ethier, 1995; Le Bourhis et al., 2000) . For example, insulin-like growth factors, transforming growth factora and fibroblast growth factors can all stimulate the proliferation of breast cancer cells, whereas mammaryderived growth factor inhibitor and transforming growth factor-b inhibit their growth. We have previously demonstrated that nerve growth factor (NGF), the first discovered neurotrophic factor, is also a potent activator of both the survival and proliferation of breast cancer cells (Descamps et al., 1998 (Descamps et al., , 2001a ). In addition, the level of NGF receptor expression has some prognostic value (Descamps et al., 2001b) and the antiestrogen drug tamoxifen, which is widely used in breast cancer therapy, is able to inhibit the mitogenic effect of this neurotrophin in breast cancer cells (Chiarenza et al., 2001) .
NGF was originally isolated for its ability to stimulate both survival and differentiation in peripheral neurons, later becoming the archetypal member of the neurotrophin family of polypeptides (Levi-Montalcini, 1987; Barbacid, 1995) . A major biological function of NGF is the maintenance and survival of postmitotic neurons, which make it a strong candidate for the treatment of neurodegenerative diseases. In addition to its role in the development and maintenance of neuronal cells, NGF also has significant effects on non-neuronal cells. For example, it triggers chemotaxis in melanocytes (Yaar et al., 1991) , inhibits the migration of Schwann cells (Anton et al., 1994) , has been reported to stimulate the proliferation of chromaffin cells (Lillien and Claude, 1985) and is also an autocrine survival factor for B lymphocytes (Torcia et al., 1996) . NGF generates intracellular signals by interacting with two classes of membrane receptors: the TrkA proto-oncogene product, p140 trkA , that possesses intrinsic tyrosine kinase activity, and a secondary receptor, p75 NTR , that belongs to the tumor necrosis factor (TNF)-receptor family (Sofroniew et al., 2001) . In breast cancer cells, we have demonstrated the presence of both p140
TrkA and p75 NTR (Descamps et al., 1998 (Descamps et al., , 2001a . The mitogenic effect of NGF requires p140 trkA and the MAP-kinase cascade, whereas the promotion of cell survival is dependent on p75 NTR and the downstream activation of NF-kB (Descamps et al., 2001a; El Yazidi-Belkoura et al., 2003) . In addition, it has been suggested that NGF might cooperate with pl85 HER2 for the activation of human breast carcinoma cell growth (Tagliabue et al., 2000) . The potent biological effect of NGF for breast cancer cells raises the question of its distribution in the mammary gland. As the effect of NGF on breast epithelial cells was not hitherto suspected, its expression in mammary tissue has not been well studied. It is generally hypothesized that NGF is produced by targets of sympathetic and sensory innervation, although it is also found in circulating blood (Bonini et al., 1996) . Provisional evidence for the presence of NGF in breast is some immunoreactivity along with the presence of suggestive biological activity in murine milk (Grueters et al., 1985) . In humans, immunoreactivity for NGF has been alluded to for breast capsule implants (Lossing and Hansson, 1993) , although its distribution in normal and cancerous breast has yet to be defined.
In the present study, we demonstrate that NGF is produced by breast cancer cells themselves, although there is no production by normal breast epithelial cells (NBECs). Importantly, the production of NGF leads to the stimulation of cell growth, showing that this neurotrophin acts as an autocrine trophic factor in breast cancer.
Results

NGF expression in breast cancer cells
The expression of NGF by breast cancer cells (MCF-7, T47D, MDA-MB-231, BT20) and NBECs was examined using reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting and enzyme-linked immunosorbent assay (ELISA). The results (Figure 1 ) demonstrated that cancerous breast epithelial cells expressed an ngf transcript visualized at 74 bp after RT-PCR. Similarly, a 74 bp transcript was detected in the human submaxillary glands, a known source of NGF, that was used here as a positive control. Moreover, NGF protein was immunodetected in both breast cancer cells and submaxillary glands as a 14 kDa band after SDS-PAGE was performed under reducing conditions. Quantification of NGF protein using ELISA revealed a similar level of NGF in all breast cancer cells that were tested. In contrast, neither NGF transcript nor protein was detected in normal breast epithelial cells (20 different primary cultures established from 20 separate biopsies were tested), suggesting that NGF expression is related to the transformation and cancer progression of breast epithelial cells.
NGF localization in breast cancer cells
The results presented in Figure 2 show that both classic immunocytochemistry and confocal microscopy could reveal NGF in breast cancer cells, whereas no labelling was seen in noncancerous cells (NBEC). Interestingly, confocal microscopy revealed the presence of NGF-rich vesicles; treatment with ionomycin, an inducer of exocytosis (Kauffman et al., 1980) , resulted in the disappearance of these NGF vesicles, suggesting the To investigate the physiological relevance of NGF production observed in breast cancer cell cultures, we performed an immunohistochemical staining of NGF in breast tumor biopsies (Figure 3 ). Invasive ductal carcinomas, which represent the majority of breast tumors, were tested and we have detected NGF in cancerous epithelial cells. Interestingly, a strong NGF immunoreactivity was found in all tumoral cells of the studied tumors. In contrast, NGF was not detected in breast epithelial cells from normal breast biopsies. Together, these results confirm the observation made in vitro that NGF is physiologically produced by breast cancer cells and not by normal breast epithelial cells.
Biologically active NGF is released by breast cancer cells
To investigate whether the NGF released by breast cancer cells was biologically active, we cocultured MCF-7 cells along with embryonic neuroprecursor cells. Our previous studies have shown that substrate-bound laminin can stimulate neurite outgrowth in the presence of exogenously added NGF, provided that cells are cultured for longer than 6 h in a serum-free medium (Small et al., 1995) . The effect of MCF-7 conditioned medium on neurite outgrowth from sympathetic neurons cultured on laminin was compared with that triggered by NGF (Figure 4 ). Cultures were grown for 48 h, and the percentage of neurons with neurites and neurite length was determined ( Table 1 ). The conditioned medium induced a threefold increase in the number of neurons with neurites and a threefold increase in neurite length. Neurons cultured in a conditioned medium concentrated with Amicon concentration cones, exhibited a 10-fold increase in the number of neurons with neurites and a 10-fold increase in neurite length compared with neurons cultured in normal conditioned medium. Anti-NGF antibodies, but not anti-BDNF or anti-NT3, could abrogate the effects of the concentrated conditioned medium in a doseresponse manner.
Autocrine stimulation of breast cancer cell growth by NGF Breast cancer cells are known to exhibit a basal level of proliferation when grown in a serum-free medium, illustrating their ability to divide without exogenous growth factor stimulation. We have investigated the possibility of NGF involvement in basal MCF-7 cell growth through treatment with both anti-NGF and K252a. Our results indicated that neutralizing anti-NGF antibody could inhibit the basal growth of MCF-7 cells ( Figure 5 ); this was not observed with a control antibody. Similar results were obtained with the other breast cancer cell lines (MDA-MB-231, T47-D and BT20 (data not shown)). In addition, treatment with K252a also inhibited the growth of MCF-7 cells in a dose/ response manner ( Figure 5 ). Almost complete blockade of breast cancer cell growth could be achieved with either anti-NGF or K-252a. Given that breast cancer cells express the tyrosine kinase receptor TrkA (Descamps et al., 1998 (Descamps et al., , 2001a , our results show that stimulation of TrkA by endogenously produced NGF can result in the stimulation of breast cancer cell growth through an autocrine loop.
Discussion
NGF stimulates proliferation of breast cancer cells through p140
TrkA receptors and the MAP-kinase pathway, whereas the antiapoptotic effect is mediated by (Descamps et al., 2001a; El Yazidi-Belkoura et al., 2003) . In the present study, we have demonstrated that NGF is produced and secreted by breast cancer cells. This NGF is biologically active and acts as an autocrine factor. In contrast, NGF synthesis and secretion by normal breast epithelial cells could not be detected. The autocrine stimulation of breast cancer cells is an important mechanism for breast tumor development (Bange et al., 2001) . Overexpression of several growth factors, and growth factor receptors, has been demonstrated; for example, insulin-like growth factor I (IGF-1) and its receptors are overexpressed by breast cancer cells as well as erb-B2 receptors. The latter overexpression has led to the development of new therapeutic strategies that utilize specific blocking antibodies (Colomer et al., 2001) . Fibroblast growth factor (FGF) and FGF receptor overexpression have also been described in breast cancer (Dickson et al., 2000) , but as FGFs are ubiquitous molecules, this relative lack of specificity has hindered the development of FGF-related therapeutic approaches. In this regard, NGF expression appears to be more tissue-specific, as relatively few cellular types have been shown to produce and release this neurotrophin.
It has long been known that NGF is produced by the targets of sympathetic nerves to attract and stabilize the resultant functional synaptic connections. NGF is produced by both neuronal and non-neuronal cell types, the latter including bladder smooth muscle cells (Clemow et al., 1998) , fibroblasts (Hattori et al., 1993) and mast cells (Leon et al., 1994) . Moreover, in the epidermis, NGF is produced by keratinocytes to stimulate both their own proliferation within autocrine loops (Di Marco et al., 1993) and the proliferation of melanocytes within the paracrine pathway (Yaar et al., 1991) . Autocrine production of NGF has also been shown for memory B lymphocytes (Torcia et al., 1996) and prostate cancer cells (Dalal and Djakiew, 1997) . In mammary gland, the expression of NGF has not been defined, and only fragmentary data are available. NGF immunoreactivity and NGF-like biological activity (Grueters et al., 1985) have been reported in mouse milk. In humans, immunoreactivity for NGF has been described in breast capsule implants (Lossing and Hansson, 1993) . Circulating NGF has also been reported in human serum (Bonini et al., 1996) , although the submaxillary gland is considered as the most important source of NGF in the body. Our results from polymerase chain reaction (PCR) and Western blot underline the absolute lack of NGF in normal breast cells and NGF quantitation was only obtained from ELISA. It appears that the submaxillary gland produces a fivefold higher amount of this growth factor than that produced by breast carcinoma cells and that levels of NGF are comparable in all the tested cell lines. The mammary gland contains substantial quantities of extracellular matrix, synthesized both by epithelial and myoepithelial cells (lamina) as well as by the fibroblasts Autocrine nerve growth factor in breast cancer cells L Dolle et al Figure 4 Neuroprecursor cell differentiation. Cell cultures were prepared from embryonic day-12 chick paravertebral sympathetic ganglia. Cells were grown on a polylysine substrate (a) and laminin (b). MCF-7 conditioned medium was added to laminin-coated dishes and induced the differentiation of neuroprecursor cells (c). Anti-NGF antibody (10 ng/ml) inhibited the neurodifferentiation induced by MCF-7 cells CM (d). MCF-7 cell CM concentrated one fold (e) and eightfold (f) were also tested TrkA and p75 NTR receptors, they are not stimulated by NGF (Descamps et al., 1998) . The absence of NGF responsiveness in normal breast epithelial cells indicates the specificity of breast cancer cells in their sensitivity to NGF, compared to their normal counterparts. Therefore, not only is NGF not synthesized by normal breast epithelial cells, but also these cells are not responsive to this growth factor. NGF production and responsiveness in breast cancer cells suggest that NGF autocrine loop is a major event in mammary carcinogenesis that potentially leads to increased survival and proliferation of tumor cells. In addition, our data suggest that NGF could be used as a marker of breast cancer cells. The prognostic value of both p75
NTR and TrkA receptors (Descamps et al., 2001b) as well as the possibility of targeting p140
TrkA -mediated mitogenic signaling with tamoxifen, a drug commonly used in breast cancer therapy, has already been reported (Chiarenza et al., 2001) . Immunohistochemistry analysis of NGF in tumor biopsies revealed differences of intensity in the carcinomas studied. We have analysed 10 different tumor biopsies and although NGF was clearly detected in all biopsies, heterogeneity in NGF intensity was found. However, at this stage of our work, it is not possible to draw any further conclusion on a potential correlation between NGF intensity and tumor type/grade.
Little is known about the mechanism by which cells process and release NGF and other neurotrophins. It is generally thought that non-neuronal cells are likely to release neurotrophins by constitutive secretion, as they do not have a regulated secretory pathway, although experimental demonstration for this is lacking. In contrast, neuronal cells contain constitutive as well as regulated secretory pathways, the latter being used to package the neurotransmitter within synaptic vesicles, and neuropeptides, such as neurotrophins, within large dense core secretory vesicles (Kelly, 1991; McAllister et al., 1999) . For example, an endogenous brain-derived neurotrophic factor in hippocampal neuronal dendrites has been localized to dense-core vesicles, which are potentially capable of undergoing regulated release (Fawcett et al., 1997; Moller et al., 1998) . Interestingly, activity-dependent secretion of NT4/5 from transfected myocytes has also been demonstrated, suggesting that non-neuronal cells release neurotrophins in a similar manner (Wang and Poo, 1997) . Our data show NGF within secretory vesicles in breast cancer cells. The permeabilizing substance, ionomycin, induces exocytosis by increasing intracellular calcium concentrations (Kauffman et al., 1980) , and its effect in our experiments suggests that NGF secretion could be functionally regulated in breast cancer cells.
An increase in the growth rate of breast cancer cells can be caused by the stimulation of both proliferation and survival of these cells, resulting in an expansion of (a) Time-dependent inhibition of basal breast cancer cell growth in a serum-free medium (&) with 1 mg/ml MAB-256 neutralizing anti-NGF (n) or with 10 nM K-252a ( Â ). Cells were counted after trypsinization with a hemocytometer. No modification of cellular growth was observed with control antibodies (not shown). (b) Dose effect of K-252a on MCF-7 cell growth and (c) dose effect of neutralizing anti-NGF. Cells were plated at 10 000/ml, and after 24 h of incubation in a serum-free medium, the indicated concentrations of anti-NGF and K-252a were added. Results presented in (a-c) represent the means7s.
d. of five independent experiments
Autocrine nerve growth factor in breast cancer cells L Dolle et al tumoral cell number. Exogenously added NGF has been shown to be a potent promoter of breast cancer cell survival and proliferation through stimulation of the tyrosine kinase receptor TrkA and the tumor-necrosis receptor family member p75 NTR , respectively (Descamps et al., 1998) . Our present study demonstrates that NGF is a physiological stimulator of breast cancer development, as this neurotrophin is overexpressed by breast cancer cells, resulting in an autocrine stimulation of tumor cell growth. Therefore, NGF now appears to be a potential marker and a potential therapeutic target that should be investigated for the definition of future strategies against breast cancer.
Materials and methods
Materials
Breast cancer cell culture reagents were purchased from BioWhittaker (Belgium) except insulin (Organon, France), fibronectin (Falcon-Biocoat, France) and transferrin (Sigma, France). The flasks and Petri dishes were obtained from Greiner (Fisher-Scientific, France). Transwell cell culture chambers were obtained from Costar (France). For neuroprecursor cell culture, Dulbecco's modified Eagle's medium and Ham's F12 medium were purchased from ICN Biomedicals Australasia Pty. Ltd (Seven Hills, Australia); amicon cones were supplied by Amicon Ultrafiltration; polylysine, putrescine, prostaglandin F2a, progesterone and bovine serum albumin were purchased from Sigma-Aldrich Pty. Ltd (Castle Hill, Australia); insulin-transferrin-selenium supplement was obtained from Life Technologies, Inc. Laminin was obtained from Collaborative Biomedical Products (Bedford, MA, USA) and cell culture plates were purchased from NuncA/S (Kamstrup, Denmark).
Recombinant human b-NGF was obtained from R&D Systems (UK). The rabbit polyclonal antibodies against NGF (sc-548) were obtained from Santa Cruz Biotechnology (Tebu, France) and trypsin was obtained from Promega (France). EGF, type XI collagenase, Hoechst 33258 and electrophoresis reagents as well as Extravidin peroxidase conjugate and 3,3 0 -diaminobenzidine were obtained from Sigma Chemical Co. (France). Glycergel was obtained from Dako (France). Molecular weight standards were obtained from Santa Cruz Biotechnology (Tebu, France). ECL reagents were obtained from Amersham Life Science (France). The antibodies used for ELISA were mouse monoclonal anti-human b-NGF (MAB-256) and specific biotinylated goat anti-human b-NGF (BAF-256). All reagents were obtained from R&D Systems. For confocal microscopy, monoclonal goat anti-rabbit IgG coupled to Alexa 488 was obtained from Molecular Probes. K-252a (inhibitor of trk-tyrosine kinase activity) was obtained from Calbiochem (France).
Breast cancer cell culture
The human breast cancer cells (MCF-7, T47D, MDA-MB-231 and BT20) were obtained from American Type Culture Collection (Rockville, MD, USA) and routinely grown in monolayer cultures. They were maintained in a minimal essential medium (Earle's salt) supplemented with 20 mm HEPES, 2 g/l sodium bicarbonate, 2 mm l-glutamine, 10% fetal calf serum (FCS), 100 U/ml penicillin-streptomycin, 50 mg/ml gentamycin, 1% of nonessential amino acids and 5 mg/ml insulin. NBEC cultures were established as described previously (Dong-Lebourhis et al., 1997; Descamps et al., 1998) from mammoplasty material obtained from the Department of Plastic Surgery of the Medical University of Lille (Pr. Pellerin, France). NBEC were cultured in DMEM/F12 (1/1) medium containing 5% FCS, 10 UI/ml insulin, 5 mm cortisol, 2 ng/ml EGF, 100 ng/ml cholera toxin, 100 mg/ml penicillin and 45 mg/ml gentamycin (B1 medium). When cells approached confluence, they were placed in the same medium except that the calcium concentration was reduced to 20 mm.
MCF-7 conditioned medium (CM)
The human breast cancer cell line MCF-7 was seeded into 75 cm 2 flasks in DMEM, FCS 10% until confluent, according to our previously published techniques (Nurcombe et al., 2000) . Upon confluence, the cells were rinsed and the medium replaced with serum-free DMEM and maintained for a further 48 h. The medium was clarified by centrifugation (800 g for 15 min) and either used fresh, or concentrated by centrifugation through Amicon-10 Centriflo cones, as per the manufacturer's instructions (Brickman et al., 1998) .
Breast cancer cell growth assay
Breast cancer cells were seeded at 2 Â 10 4 cells/ml in 35-mm dishes in a complete medium. When 40% confluence was reached, cells were washed twice and starved in a serum-free medium containing fibronectin (2 mg/ml) and transferrin (30 mg/ml) for 3 h. In the next hour, the medium was replaced by 2 ml of the same medium containing K-252a (an alkaloı¨d-like trkA inhibitor) or MAB-256 (anti-NGF blocking antibody) at different concentrations, in order to study the effect of pharmacological inhibitor or blocking antibody on the basal level of growth. After 24, 36, 48 and 72 h of treatment, cell number was determined after trypsinization of the monolayer culture with 0.25% trypsin/EDTA solution using a hemocytometer. To assess the specificity of the blocking antibody, a nonrelevant antibody was used.
Neuroprecursor cell differentiation assay
Cell culture plates (96-well) were prepared by incubating each well with 100 ml of 0.1 mg/ml poly-l-lysine in sterile distilled water for 15 min. The wells were then washed three times with 200 ml of sterile distilled water. Wells were incubated with 5 mg/ml purified glypican or 10 mg/ml perlecan in 100 ml of phosphate-buffered saline (PBS) for 2 h at room temperature. Each well was washed twice with 200 ml per well of PBS. Approximately 2 Â 10 3 cells, prepared from embryonic day-12 chick paravertebral sympathetic ganglia, were added to each well in 100 ml of a 1 : 1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 media containing 1.0% (v/v) insulintransferrin-selenium-X supplement, 100 mm putrescine, 1.67 mg/ml prostaglandin F2a, 6.67 ng/ml progesterone and 0.5 mg/ml bovine serum albumin, with or without 10 ng/ml bNGF. Cultures were grown for 48 h, fixed with 2% (w/v) glutaraldehyde in PBS, and then examined by phase-contrast microscopy. Selected fields were captured for computerassisted image analysis (Metamorph, Australia). The percentage of neurons with neurites was determined in 10 separate fields around the center of each well. On average, 60 neurons were counted per well. For the analysis of neurite length, the longest neurite on 20 neurons bearing neurites in each well was measured. A minimum of four wells for each treatment group were analysed. Differences between the means of controls and each treatment group were analysed by a two-tailed Student's t-test. Means were assumed to be significantly different when the P-value for the null hypothesis was less than 0.05.
Reverse transcription-polymerase chain reaction
Total RNA was isolated from breast cancer cell lines and from human submaxillary gland (20 mg weight) using the RNeasy Mini Kit (Qiagen, France). The disruption and homogenization of the submaxillary gland were performed using a RotorStator Homogenizer (Ribolyser, Hybaid). The amount of extracted RNA was quantified by measuring the absorbance at 260 nm, and the purity of the RNA was checked by the ratio of the absorbance at 260 and at 280 nm. The absence of degradation of the RNA was confirmed by electrophoresis of the RNA on a 1.5% agarose gel containing ethidium bromide. The reverse transcription reaction mixture contained 2 mg of purified total mRNA, 1 Â reverse transcription reaction buffer, 10 mm DTT, 400 mm dNTP each, 2.5 M oligo(dT), 40 U of RNasin and 200 U of Moloney murine leukemia virus reverse transcriptase were added to 25 ml of the total reaction volume. All the reaction mixtures were incubated at 371C for 1 h and then inactivated at 951C for 5 min. PCR was performed on cDNAs after RT or corresponding total RNA samples without the RT step for negative controls. The primers used for ngf RT-PCR detection in these cell lines were as follows: ngf sense primer, 5 0 -GACAGTGTCAGCGTGTGGGTT-3 0 and antisense primer 5 0 -CCCAACACCATCACCTCCTT-3 0 . To PCR tubes, 5 ml of PCR buffer (200 mm Tris-HCl, pH 8.4, 500 mm KCl), 10 ml of 15 mm MgCl 2 , 1 ml of 10 -mm dNTP mix, 1 ml of cDNA or total mRNA (for negative control), 1 ml of 50 -mm respective primers, 1 ml of 2.5 U/ml Taq DNA polymerase and water to a total volume of 50 ml were added. The PCR conditions were as follows: after 951C for 3 min for denaturing cDNA, 30 cycles were run at 941C for 1 min, 571C for 2 min and 721C for 3 min. The PCR tubes were incubated for a further 10 min at 721C for the extension of cDNA fragments after the final cycle. The amplified material was visualized under UV light by ethidium bromide staining following agarose gel electrophoresis.
Immunoblotting
Subconfluent cell cultures were rinsed and placed in a serumfree medium containing fibronectin and transferrin for 24 h. After starvation, cells were harvested by scraping in PBS buffer and were subjected to centrifugation (1000 g, 5 min). The pellet was treated with lysis buffer (10% SDS, 0.5% bmercaptoethanol, 0.5 m Tris-HCl pH 6.8, 25% glycerol, 0.5%) and boiled for 5 min at 1001C. After a centrifugation (1000 g, 5 min), the supernatants were assayed for proteins using Bio Rad protein assays. The lysates from each cell line (100 mg of proteins) and from the submaxillary gland were subjected to SDS-PAGE, transferred onto a nitrocellulose membrane by electroblotting (200 mA, 45 min) and blocked with 1% bovine serum albumin in tris-buffered saline pH 7.4 (TBS-T, 0.1% Tween 20). Each membrane was then probed with a rabbit polyclonal anti-NGF antibody at 41C overnight. The membrane was rinsed three times with TBS-T buffer and it was then incubated at room temperature for 2 h with a horseradish peroxidase-conjugated anti-rabbit immunoglobulin. The membrane was rinsed four times with TBS-T buffer and the reaction was revealed using the ECL chemiluminescence kit (Amersham Pharmacia Biotech) with Kodak X-Omat AR film.
Enzyme-linked immunosorbent assay
A two-site ELISA for human b-NGF was used. Briefly, immunoplates were coated with 1 mg/ml capture monoclonal antibody (MAB-256) diluted in diluent buffer (0.1% BSA, 0.005% Tween 20 in Tris-buffered saline, pH 7.3). Control wells were coated with the same amount of mouse IgG. Each well received 100 ml of this dilution and the dishes were sealed and incubated at room temperature overnight. Wells were washed three times with 400 ml of PBS, pH 7.4, containing 0.05% Tween 20. The plates were then blocked at room temperature using 1% bovine serum albumin, 5% sucrose and 0.05% NaN 3 in the same buffer. After 2 h, each well was washed, dilutions of unknowns and standards were applied in a volume of 100 ml and the plates were covered overnight at room temperature. Human b-NGF was used as a standard sample from 0.25 to 8 ng/ml in 100 ml of the diluent buffer. The plates were then washed extensively and the detection biotinylated antibody (BAF-256) was added at 50 ng/ml before incubation for 2 h at room temperature. After incubation, the immunoplates were washed three times with washing buffer and 100 ml of streptavidin horseradish peroxidase was added for a 20-min incubation at room temperature. The reaction was started by adding 100 ml of substrate solution for 30 min of incubation at room temperature and in darkness. After this time, 50 ml of stop solution (H 2 SO 4 1 m) was added to each well. The optical density was determined within 30 min using a microplate reader set to 595 or 450 nm. All determinations were in triplicate, and data are the means of three independent experiments.
Immunocytochemistry and immunohistochemistry
Immunocytochemical analysis for NGF detection was performed on both normal and cancerous breast epithelial cells. The medium was carefully aspirated from the culture dishes, which were then washed with PBS before incubation in a blocking solution for 2 h. The cultures were washed and fixed by ice-cold methanol for 30 min and preincubated with 0.1% hydrogen peroxide for 1 h at room temperature in order to block endogenous peroxidase activity. They were then incubated overnight at 41C with a mouse monoclonal anti-human b-NGF antibody (R&D System), followed by 2 h at room temperature with biotinylated antimouse IgG antibodies diluted 1/250 and 2 h at room temperature with avidin/biotin-peroxidase complex diluted 1/200. In controls, the first antibodies were omitted to ensure specificity of the primary antibodies. After the reaction occurred, the dishes were coverslipped in Glycergel, examined and photographed.
For analysis of normal and cancer breast biopsies, invasive ductal breast carcinoma specimens were obtained from 10 patients treated by mastectomy at the Centre de Lutte Contre le Cancer (Lille, France). These cases have been extensively characterized and reported (Adriaenssens et al., 1998) . Noncancerous mammary gland biopsies provided from mammoplasty material were obtained from the Department of Plastic Surgery (Professor Pellerin) of the Medical University of Lille (France). Immediately after resection, the material was fixed with formalin (10%) for 24 h and then dehydrated through increasing ethanol concentrations and embedded into Paraplast Plus. Microtome sections were prepared at a thickness of 5 mm and allowed to transfer to slides coated with 3-aminopropyl-triethoxysilane (TESPA, Aldrich) for immunohistochemical staining. Sections were then fixed on a slide by a glycerinated albumin (10%) solution. Hemalun-phloxine-safran (HPS) staining was performed on one section of tumors and normal tissue to indicate histological structures, heterogeneity of tumors and to localize precisely the more interesting areas to be observed by immunohistochemical staining procedures. To remove paraffin from tissues, sections were deparaffinized and rehydrated. To enable to recognize antigen (NGF) and not endogenous peroxidase activity specifically, sections were treated with 0.1% hydrogen peroxide for 1 h in order to quench this endogenous activity. Then, sections were placed in TBS-T (0.05% Tween 20 in tris-buffered saline, pH 7.4; 1 h) 3% BSA to block nonspecific antigens. Anti-NGF rabbit polyclonal antibody (1/50 in TBS-T 3% BSA) was added at room temperature in a moist chamber. After 1 h, sections were rinsed with TBS-T three times and then incubated 1 h with a biotinylated anti-rabbit IgG antibody. After two washings in TBS-T, streptavidin-horse radish peroxidase solution was added for 30 min. Sections were rinsed in TBS-T, and immunoreactivity was visualized with diaminobenzidin chromogen. Finally, sections were counterstained with hematoxylin to contrast cell nuclei and slides were then coverslipped and read using a light microscope. Photomicrographs were taken with a phase-contrast microscope connected to an Olympus optical Camedia digital camera. Negative controls were obtained by exclusion of the primary or secondary antibodies.
Confocal microscopy
Cells were treated or not treated 1 h with ionomycin (100 mm). Cells cultured onto glass coverslips coated with collagen were washed twice with PBS and then fixed with PBS containing 4% paraformaldehyde for 30 min at room temperature. After washing with ammonium chloride (10 min at room temperature), cells were permeabilized with 0.05% saponin in PBS (10 min) and blocked for 10 min in a permeabilizing buffer (PBS containing 2% BSA and 0.05% saponin). Then, the cells were successively incubated for 1 h at room temperature with anti-NGF (1/200). After five washes with the permeabilizing buffer, cells were incubated with secondary antibodies (30 min, 371C at a 1 : 100 dilution). Cells were washed twice with the permeabilizing buffer and twice with PBS-2% BSA and then, with PBS alone. Slides were mounted using Vectashield (Vector Laboratories). Fluorescence-stained slides were examined under a Leica TCS NT laser scanning confocal microscope comprising a krypton/argon laser (with 488, 568 and 647 nm excitations possible). Frame scanning was performed at 1000-fold magnification and a single optical section was collected per field.
Abbreviations NGF, nerve growth factor; NBEC, normal breast epithelial cell; RT-PCR, reverse transcription-polymerase chain reaction; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; TBS, tris-buffered saline; FCS, fetal calf serum.
